Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of L-Nil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 4/20 | 0.51 |
| ▸ | NOS2 | P35228 | 6/20 | 0.50 |
| ▸ | NOS1 | P29475 | 5/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | OTC | P00480 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Nil SCHEMBL1321685 | 1.00 | ARG2 (0.51) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL7974005 | 1.00 | ARG2 (0.51) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL7977021 | 1.00 | ARG2 (0.51) | ARG2NOS2NOS1BLMARG1 | |
| Hydrochloric Acid SCHEMBL8470176 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL31540966 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL934874 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nil SCHEMBL322091 | 0.98 | ARG2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| SCHEMBL8065968 | 0.97 | NOS2 (0.50) | ARG2NOS2NOS1BLMARG1 | |
| L-Nio SCHEMBL676368 | 0.95 | OTC (0.53) | ARG2NOS2NOS1BLMARG1 | |
| L-Nio SCHEMBL1320520 | 0.95 | OTC (0.53) | ARG2NOS2NOS1BLMARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1171861-C | halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors | GD | 2004-10-20 | — | — | CN | claimed |
| CN-1292779-A | Haloamidino amino acid derivatives as nitric oxide synthase inhibitors | SEARLE & CO (US) | 2001-04-25 | — | — | CN | claimed |
| US-20240041869-A1 | OPHTHALMIC COMPOSITION COMPRISING AN ANTI-ALLERGEN AND A REDNESS REDUCTION AGENT | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-02-08 | — | — | US | disclosed |
| US-9522163-B2 | Methods of treating hepatitis | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2515917-B1 | BRIMONIDINE FOR EYE WHITENING | EYE THERAPIES LLC (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8765758-B2 | Compositions and methods for eye whitening | EYE THERAPIES LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140141103-A1 | METHODS OF TREATING HEPATITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-22 | — | — | US | disclosed |
| US-20130202720-A1 | METHODS OF TREATING HEPATITIS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2012149381-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NIGHT VISION | Alpha Synergy Development, Inc. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120276220-A1 | Method of Treating Hepatitis | YALE UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277239-A1 | Compositions and Methods for Improving Night Vision | ALPHA SYNERGY DEVELOPMENT INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110160214-A1 | Compositions and methods for eye whitening | Alpha Synergy Development, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110003823-A1 | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage | Alpha Synergy Development, Inc. | 2011-01-06 | — | — | US | disclosed |
| US-20080171021-A1 | PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| CN-1171861-C | halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors | GD | 2004-10-20 | — | — | CN | disclosed |
| US-20040131703-A1 | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | disclosed |
| US-20040052866-A1 | Methods of treating hepatitis | PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2004-03-18 | — | — | US | disclosed |
| US-20040043992-A1 | Meloxicam for alleviating organ injury during organ operation or transplantation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2003097066-A1 | USE OF MELOXICAM FOR ALLEVIATING ORGAN INJURY DURING ORGAN OPERATION OR TRANSPLANTATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-27 | — | — | WO | disclosed |
| CN-1292779-A | Haloamidino amino acid derivatives as nitric oxide synthase inhibitors | SEARLE & CO (US) | 2001-04-25 | — | — | CN | disclosed |